Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21377761 | 0.93 | TSHR (0.43) | TSHREPHX2 | |
| SCHEMBL24064873 | 0.87 | — | — | |
| SCHEMBL14456664 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL3544633 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL3545812 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL3542649 | 0.82 | — | — | |
| SCHEMBL3542888 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL3195805 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL19590919 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 | |
| SCHEMBL3546432 | 0.82 | ALDH1A1 (0.48) | ALDH1A1EPHX1HIF1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | TSHR 716/4885ALDH1A1 2812/4885EPHX1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.